Skip to main content
Jue Wang, MD, Oncology, Dallas, TX, St. Joseph's Hospital and Medical Center

JueWangMD

Oncology Dallas, TX

Assistant Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine

Are you Dr. Wang?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 28 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Jue Wang, MD is an oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas, Arizona, and Nebraska. He is affiliated with University of Texas Southwestern Medical Center and is an Assistant Professor at University of Nebraska Medical Center College of Medicine.

Education & Training

  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 2005 - 2007
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2002 - 2005
  • Suzhou Medical College
    Suzhou Medical CollegeClass of 1990

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2014 - 2025
  • TX State Medical License
    TX State Medical License 2023 - 2025
  • NE State Medical License
    NE State Medical License 2007 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FACP) American College of Physicians, 2011

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-Low-Positive and HER2-Zero Breast Cancer
    Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-Low-Positive and HER2-Zero Breast CancerJanuary 19th, 2023
  • NMPA Approves IND Application for CT103A, a Fully-Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Biologics
    NMPA Approves IND Application for CT103A, a Fully-Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent BiologicsOctober 2nd, 2019
  • Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings
    Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual MeetingsJune 19th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations